A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions

Melanoma MetastaticUveal Melanoma, MetastaticMucosal Melanoma

Interventions

DRUG

[225Ac]Ac-A9-3408

Administered IV

DIAGNOSTIC_TEST

[68Ga]Ga-A9T-3202

Administered IV

Trial Locations (3)

Alfred Health, Melbourne

Fiona Stanley Hospital, Murdoch

GenesisCare Murdoch, Murdoch